Insight on the Evolving Management of High-Risk Resectable Melanoma (Ahmad Tarhini, MD, PhD)
- Initial evaluation of Stage III melanoma
- Biomarker testing
- Benefits and risk of adjuvant therapy
- Exploring neoadjuvant therapy
Clinical Advances for Optimizing Outcomes in Metastatic Melanoma (Michael A. Davies, MD, PhD)
- BRAF/MEK inhibitor combinations for BRAF-mutated melanoma
- Checkpoint inhibitor monotherapy and combinations
- Strategies for managing CNS metastases
Panel Discussion and Audience Q&A
Date / Time
Michael Davies, MD, PhD
Professor and Chair
Department of Melanoma Medical Oncology
University of Texas MD Anderson Cancer Center
Ahmad Tarhini, MD, PhD
Senior Member, Departments of Cutaneous Oncology & Immunology
Director, Cutaneous Clinical and Translational Research
H. Lee Moffitt Cancer Center and Research Institute
Professor, Department of Oncologic Services
University of South Florida Morsani College of Medicine
The goal of this activity is to improve the knowledge, competence, and performance of learners to plan individualized treatment for patients with melanoma.
This program is intended for oncologists, dermatologists, advanced practitioners, nurses, pharmacists, and other healthcare providers involved in the care of patients with melanoma.
Upon completion of this activity, participants should be able to:
- Create individualized treatment strategies using biomarkers, clinical characteristics, mutational analyses, and patient preferences to individualize frontline and subsequent treatment approaches for patients with melanoma
- Integrate emerging data on therapeutic sequencing options into the context of treatment for patients with melanoma
- Evaluate the efficacy and safety evidence of combination regimens to individualize therapeutic strategies for patients with melanoma at first relapse
- Plan appropriate treatment strategies using all available agents and classes to provide efficacious combination therapies to heavily pretreated patients with relapsed/refractory melanoma
- Develop a proactive management plan for adverse events associated with targeted and immunotherapeutic approaches used to treat melanoma
- Evaluate emerging data with novel investigational targeted and immunotherapeutic approaches to aid in clinical trial participation
- Enhance communications between patients with melanoma and their physicians by increasing patient understanding of the complexities of their disease, its prevention, risks, diagnosis, management, and clinical prognosis
- Explain the available therapeutic options, management strategies, disease management interventions, and clinical outcomes in melanoma to patients, family members, and caregivers
- Inform patients on the need for and risks of pharmacotherapies, chemotherapy, radiation therapy, surgery, and other interventions and how this may benefit their disease state, as well as what the potential outcomes may be, as part of enhancing patient informed consent to facilitate patient–physician communication and the decision-making process and partnership
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-103-L01-P
Type of Activity: Knowledge
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.